Head and Neck Cancer Studies Currently Recruiting Participants at the University of Chicago Comprehensive Cancer Center

Study Number Title
8980 Tissue Procurement and Laboratory Core
15410A Utilization of Previously Banked Tissues from Patients with Head and Neck and Lung Cancer for Analysis of DNA repair markers and Correlation With Clinical Data
Select
09-266-B Randomized Phase II Trial of Everolimus versus Placebo as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Select
10-069-B Selection of Chemoradiotherapy Based on Response to Induction Chemotherapy A Phase 2 Study in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
10-540-B Observational Study of Swallowing Function after Treatment of Advanced Laryngeal Cancer
Select
11-0032 A Pilot Feasibility Study of 99mTc EC DG SPECT/CT Imaging in the Treatment Response Evaluation in Patients with Locally Advanced Head and Neck Cancer
Select
11-0265 Randomized Placebo- Controlled Phase II Study of ZD6474 as a Chemopreventive Agent for Premalignant Lesion of the Head and Neck
Select
12-1554 Nab-Paclitaxel-based re-induction chemotherapy followed by response-stratified chemoradiotherapy in patients with previously treated squamous cell carcinoma of the head and neck.
Select
12-2054 A phase Ib dose escalation/randomized phase II, multicenter, open-label study of BYL719 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma
Select
13-0311 A Phase Ib Multi-Cohort Study of MK-3475 in Subjects with Advanced Solid Tumors
Select
IRB13-0936 A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
Select
IRB13-1454 A Phase 1b, Open-Label, Multicenter Study of Urelumab (BMS-663513) in Combination with Cetuximab in Subjects with Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck
IRB14-0081 Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients with Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma

To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.